Table 1.

Demographic characteristics of TCGA samples.

	LN-negative	LN-postive	p
N	128	115
Race (%)			0.355
NA	3 (2.3)	0 (0.0)
American Indian or Alaska native	0 (0.0)	1 (0.9)
Asian	6 (4.7)	5 (4.3)
Black or African American	23 (18.0)	17 (14.8)
White	96 (75.0)	92 (80.0)
Number of positive lymphnodes by HE (mean (sd))	0.00 (0.00)	7.13 (5.71)	<0.001
Progesterone receptor status (%)			0.035
NA	9 (7.0)	10 (8.7)
Indeterminate	0 (0.0)	1 (0.9)
Negative	54 (42.2)	29 (25.2)
Positive	65 (50.8)	75 (65.2)
Estrogen receptor status (%)			0.01
NA	8 (6.2)	10 (8.7)
Indeterminate	0 (0.0)	1 (0.9)
Negative	46 (35.9)	20 (17.4)
Positive	74 (57.8)	84 (73.0)
HER2 immunohistochemistry receptor status (%)			0.026
NA	15 (11.7)	26 (22.6)
Equivocal	28 (21.9)	12 (10.4)
Indeterminate	0 (0.0)	1 (0.9)
Negative	69 (53.9)	57 (49.6)
Positive	16 (12.5)	19 (16.5)
Therapy types (%)			0.019
NA	36 (28.1)	24 (20.9)
Ancillary	1 (0.8)	1 (0.9)
Chemotherapy	55 (43.0)	73 (63.5)
Chemotherapy and hormone therapy	0 (0.0)	1 (0.9)
Hormone therapy	34 (26.6)	12 (10.4)
Immunotherapy	1 (0.8)	1 (0.9)
Targeted molecular therapy	0 (0.0)	1 (0.9)
Other	1 (0.8)	2 (1.7)
Pathologic stage (%)			<0.001
Stage II	3 (2.4)	1 (0.9)
Stage IIA	106 (82.8)	8 (7.0)
Stage IIB	15 (11.7)	26 (22.6)
Stage III	0 (0.0)	2 (1.7)
Stage IIIA	0 (0.0)	53 (46.1)
Stage IIIB	4 (3.1)	3 (2.6)
Stage IIIC	0 (0.0)	22 (19.1)
Age at initial pathologic diagnosis (mean (sd))	54.87 (9.19)	52.43 (9.08)	0.039
Vital status follow up (%)			0.142
NA	2 (1.7)	3 (2.8)
Alive	111 (91.7)	89 (83.2)
Dead	8 (6.6)	15 (14.0)
OS time (mean (sd))	1108.70 (1069.91)	1416.06 (1426.87)	0.091